Charles Schwab Investment Management Inc. Sells 20,536 Shares of DaVita Inc. (NYSE:DVA)

Charles Schwab Investment Management Inc. cut its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 4.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 468,721 shares of the company's stock after selling 20,536 shares during the period. Charles Schwab Investment Management Inc. owned about 0.61% of DaVita worth $71,700,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. United Capital Financial Advisors LLC raised its holdings in shares of DaVita by 2.6% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock valued at $361,000 after purchasing an additional 62 shares during the last quarter. Freedom Investment Management Inc. raised its holdings in shares of DaVita by 3.6% in the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock valued at $268,000 after purchasing an additional 62 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of DaVita by 2.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock valued at $531,000 after purchasing an additional 69 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in DaVita by 8.9% during the first quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock worth $148,000 after buying an additional 79 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. This trade represents a 8.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 1.50% of the stock is currently owned by company insiders.

DaVita Trading Up 0.7%

Shares of DaVita stock traded up $0.96 on Friday, hitting $135.35. The stock had a trading volume of 721,001 shares, compared to its average volume of 925,075. The stock has a 50 day moving average of $139.68 and a 200 day moving average of $145.28. DaVita Inc. has a twelve month low of $126.07 and a twelve month high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. The firm has a market capitalization of $9.68 billion, a P/E ratio of 13.31, a PEG ratio of 0.97 and a beta of 1.09.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.70 by $0.25. The business had revenue of $3.38 billion for the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%. The firm's revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.00 earnings per share. Sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

DVA has been the topic of a number of recent analyst reports. Truist Financial set a $148.00 target price on shares of DaVita in a report on Friday, August 8th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Finally, Barclays cut their price objective on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.